Signal transduction pathways are largely based on compilation of individual post-translational 25 modification assays in heterogeneous cellular contexts. Indeed, de novo reconstruction of 26 signaling interactions from large-scale molecular profiling is still lagging, compared to similar 27 efforts in transcriptional and protein-protein interaction networks. To address this challenge, we 28 present systematic, computational reconstruction of tyrosine kinase (TK) signal transduction 29 pathways, based on mass spectrometry-based proteomics profiling of phosphotyrosine-enriched 30 2 peptides from 250 samples representative of lung adenocarcinoma. The network represents 43 31
Introduction 41
Lung adenocarcinoma (LUAD) is a leading cause of cancer related deaths in United States, 42
representing 40% of the 225,500 new lung cancer cases every year and a 5-year survival rate of 43 only 16 % (1). Excluding immunotherapeutic agents, which have recently shown significant 44 success in a relatively small subset of patients (2), the most effective targeted therapies for this 45 diseases were designed to inhibit tyrosine kinases harboring genetic alterations inducing aberrant 46 activation of downstream signaling pathways (3-7). These events primarily include EGFR 47 mutations and ALK-EML4 fusion events, in ~15% and ~3-7% of LUAD patients, respectively (8, 48 9 ). Yet, while targeted therapy is initially effective in a significant fraction of patients harboring 49 these actionable alterations, the vast majority of them will either fail to respond or develop 50 resistance to mono-therapy (10, 11). In addition, most patient lack actionable alterations 51 altogether. This suggests that novel approaches are critically needed. 52
A possible alternative to minimize emergence of resistance is combination therapy, a strategy 53 that has been shown to be effective in many metastatic tumors, such as breast cancer, and acute 54 myeloid leukemia (12-14). However, systematic identification of effective drug combinations on a 55 genetic alteration basis is difficult, because the number of patients presenting multiple actionable 56 events is extremely low. As a result, combination therapy is generally hypothesized and tested on 57 an empirical basis or based on elucidation of complex mechanisms of tumor cell adaptation. To 58 address these limitations, we and other have proposed that rational design of combination therapy 59 will require a more mechanistic and tumor-context-specific understanding of the molecular 60 interactions that underlie their potential synergistic activity, starting with tyrosine kinases, which 61 represent a critical class of pharmacological targets in cancer (15) . Such an approach requires 62 methodologies for the accurate and systematic elucidation of tumor-specific signaling 63 transduction pathways. 64
Dissection of signal transduction networks represents a complex endeavor, requiring elucidation 65 of hundreds of thousands of tissue-specific molecular interactions that mediate the post-66 translational modification of protein substrates. In vitro approaches generally fail to capture the 67 tissue-specific nature of these interactions, thus providing "average" signal transduction pathways 68 that are both incomplete and inaccurate. In addition, experimental approaches that have been 69 successful in accelerating the analysis of molecular interactions in transcriptional regulation and 70 protein-protein interaction in stable-complexes, such as those based on co-expression or yeast-71 2-hybrid assays, do not easily translate to elucidating signaling interactions. Similarly, approaches 72 based on the use of phospho-specific antibodies, while elegant and effective, are limited to only 73 a handful of proteins. Computationally, compared to the many algorithms that have been 74 developed for the reverse engineering of transcriptional and protein-complex interactions (16, 17), 75 only a handful of experimentally validated algorithms are available for the dissection of signaling 76 networks, none of which works at the proteome-wide level or is tumor-context specific (16, 18, 77 19) . 78
Recent availability of proteome-wide molecular profile data, characterizing the abundance of 79 phospho-tyrosine-enriched peptides by liquid chromatography coupled to tandem mass 80 spectrometry (LC-MS/MS), suggests that additional methodologies may be developed to extend 81 approaches that have been successfully applied to the dissection of transcriptional networks from 82 gene expression profiling. In this manuscript, we propose extending the Algorithm for the 83 Reconstruction of Accurate Cellular Networks (ARACNe) (26) for the reverse engineering of 84 signal transduction networks from large-scale phosphoproteomic profiles. The new method, 85 pARACNe, addresses critical issues that prevented the direct application of the original ARACNe 86 algorithm on phosphoproteomic datasets. In particular, it has been modified to handle the highly 87 sparse nature of phosphopeptide abundance data, the large amount of noise and missing data, 88 7 of these assumptions of ARACNe are violated in proteome-wide datasets generated by the most 134 popular methods based on data-dependent acquisition. Particularly when employing 135 quantification by spectral counting, as is typically conducted for global protein-protein interaction 136 studies [PMID: 26186194, 28514442], phosphoproteomic data is both discrete (i.e., generally 137
represented by spectral counts), very sparse, with a majority of peptides having zero spectral 138 counts, and presenting a significantly skewed distribution for low-abundance peptides. 139
140
To address these limitations, we developed an entirely novel algorithm, pARACNe (phospho-141 ARACNe) ( Fig. 1C) , specifically designed to measure phospho-state dependencies between TKs 142 and their candidate substrates using large-scale LC-MS/MS phosphoproteomic profiles. 143 pARACNe thus extends the original ARACNe framework to allow systematic inference of TK→S 144 interactions. Specifically, to handle the highly discrete nature of the data, pARACNe replaces the 145 kernel-density and adaptive partitioning based mutual information estimators with the naive 146 method (Fig 1C4) , using gold standard data to select the most effective number of bins [12] (see 147
Methods). Furthermore, to deal with the skewed spectral count distribution, we introduce an 148 iterative quantile discretization method, where samples are binned together, based on their 149 spectral counts, to produce a distribution as close to uniform as possible (Fig 1C3, Methods) . 150 151
pARACNe-inferred LUAD-specific TK-phosphorylation network 152
We used pARACNe to reconstruct a LUAD-specific TK-signaling network, by analyzing 153 phosphopeptide profiles obtained from 245 LUAD samples (34). These data represent the 154 abundance of peptides containing at least one phospho-tyrosine, as obtained by 155 phosphoproteomic analysis of 46 LUAD cell lines, 151 LUAD tumors, and 48 adjacent normal 156 samples. LC-MS/MS profiling identified 3920 phospho-tyrosine residues on approximately 2600 157 different proteins. Based on these data, pARACNE identified a total of 2611 peptide-peptide 158 interactions, which could be further mapped to 2064 unique TK→S interactions (Suppl . Table 1) . 159
The latter represent interactions between 46 distinct TKs and their candidate substrates, including 160 174 TK 1 →TK 2 interactions between two TKs (Fig 2A) , which represents a statistically significant 161 bias toward TK-TK interactions in the network (p = 10 -62 ). This suggests that TKs may form a more 162 densely inter-connected subnetwork within the complete TK signaling network than previously 163 assessed, thus potentially providing critical novel information about adaptive response, pathway 164 cross-talk, and auto-regulatory loops. Indeed, such highly interconnected structure provides 165 potential functional advantage compared to less connected or "flat" architectures, including the 166 ability to provide more fine-grain response to a highly heterogeneous variety of exogenous signals 167 and conditions, the ability to provide rapid adaptive response to changing stimuli, and the ability 168 
LUAD Network Accuracy and Sensitivity Analysis 180
To estimate the accuracy of the inferred TK-signaling network, we investigated the substrates of 181 two TK-proteins, EGFR and c-MET, representing high-affinity binding targets of existing FDA-182 approved TK inhibitors for LUAD. Specifically, we compared their pARACNe-inferred substrates 183 to those reported in the phosphoDB database (35) and those supported by experimental 184 evidence, based on previously published SILAC assays, following cell line treatment with 185 associated, selective TK inhibitors. pARACNe inferred 123 EGFR substrates (Fig 2B) . Of these, 186 5 (blue and cyan) were included as high-confidence EGFR substrates in phosphoDB, out of 13 in 187 total (38%), including the established EGFR auto-phosphorylation site. Moreover, 50 additional 188 proteins (45%, green) showed significant decrease (alteast 2 fold) in the abundance of their 189 phosphorylated isoforms in SILAC assays (34), following treatment of H3255 cells with the EGFR 190 inhibitor Gefitinib. Similarly, pARACNe predicted 179 c-MET substrates (Fig 2C) . Notably, both 191 of the established substrates reported in PhosphoDB were identified by pARACNE (100%, blue). 192
Moreover, 126 additional proteins (71.5%, blue) showed significant decrease in the abundance 193 of their phosphorylated isoforms in SILAC assays(34), following treatment of MKN45 cells with 194 the first-generation c-MET-specific inhibitor Su11274. 195
We used MKN45, even though it represents a gastric cancer cell line, to assess the overall 196 conservation of predictions in different tissues. Indeed, while specific substrates are likely to be 197 highly tumor-context specific, signaling networks should be significantly more conserved than 198 transcriptional ones, since lineage-specific chromatin states represent a major determinant of 199 transcriptional regulation, while signal transduction is only affected indirectly by the availability of 200 specific partner proteins. As a result, it is reasonable to expect that an even greater overlap of 201 inferred vs. SILAC positive substrates may be achieved in native LUAD cells. 202
203
Taken together, these data suggest that pARACNe can identify a much larger subset of candidate 204 substrates, while both identifying a significant proportion of established substrates (46% on 205 average, based on phosphoDB) and maintaining high accuracy (~60% on average, by SILAC 206 assays). This also suggest that, similar to transcription factor targets reported in the literature, TK 207 substrates are poorly characterized, even for highly relevant and exceedingly well-studied kinases 208 such as EGFR and c-MET. As a result, pARACNe could provide significant novel hypotheses for 209 TK→S interactions that can be validated as required. We should also note that the reported 210 accuracy for pARACNe is estimated using SILAC data on a single cell line. SILAC assays have 211 significant false negatives and it would be reasonable to expect that, once tested in additional cell 212 lines, the accuracy of pARACNe could further increase. As a further performance benchmark, we 213 used the same SILAC benchmark to test predictions by NetworkIN, a reverse engineering method 214 based on protein sequence motif analysis and protein association networks (16). The analysis 215 found almost no consensus with SILAC assays, with only one out of 33 NetworkIN-predicted 216 EGFR substrate identified as significantly dephosphorylated following treatment with TK-specific 217 inhibitors. 218 219
Systematic, network-based inference of pharmacological dependencies 220
Once an accurate model of signal transduction in LUAD cells was established by pARACNe 221 analysis, we interrogated the corresponding TK→S network using phosphoproteomic signatures 222 from 46 LUAD cell lines to identify key dependencies for experimental validation. For this purpose, 223
we extended the Virtual Proteomics by Enriched Regulon analysis (VIPER)(37), which had been 224 originally developed to identify key proteins controlling the transcriptional state of tumor-related 225 cells, on an individual sample basis. Specifically, VIPER was designed to identify these proteins 226 by assessing the enrichment of their transcriptional targets in differentially expressed genes, in a 227 tumor-specific gene expression signature. VIPER, which extends the Master Regulator Inference 228 algorithm (MARINa) to support analysis of single samples, has been instrumental in identifying 229 master regulator proteins representing key functional determinants of tumor-related phenotypes 230 in many cancer types, from glioblastoma (32, 33, 38), lymphoma (39, 40), and leukemia (41) to 231 prostate (42-44) and breast adenocarcinoma(45-47), among others. We thus reasoned that 232 VIPER could be modified to identify master regulator TKs, most likely to induce the differential 233 phosphorylation pattern observed in a specific tumor sample ( Fig. 3A) . Method section). Systematic VIPER analysis of phosphoproteomic profiles from 46 LUAD cell 248 lines generated between 2 and 13 master regulator TKs or synergistic TK-pairs, as candidate 249 pharmacologically actionable dependencies, for each cell line, thus generating a plausible number 250 of hypothesis for each line ( Fig. 3B and Fig 3C) . with established sensitivity to ALK inhibitor (63, 64). This further reflects the specificity of our 275 analysis as this was the only cell line predicted to depend on ALK activity. Interestingly, we 276 identified 4 additional H2228 dependencies, namely EGFR, Epha2, c-MET, and PTK2. H2228 277 sensitivity to EGFR inhibitors, in combination with ALK inhibitors, was already established (64). 278
In addition, we confirmed dependency of H2228 cells on the other 3 TKs (Epha2, c-MET and 279 PTK2) by cell viability assay following siRNA-mediated silencing of the corresponding gene, 280 (Suppl. Fig. 2A) . BrdU assays confirmed H2228 sensitivity to c-MET and PTK2 silencing (Suppl. 281 To validate pVIPER-predicted, cell line specific EGFR/c-MET synthetic lethality, we selected a 298 panel of 14 cell lines, 11 of which were predicted to be synergistically dependent on EGFR/c-MET 299 (H226, H2122, H1666, H2172, Cal-12T, H2023, H1568, Calu-3, H1650, HCC78, and A549), as 300 well as 3 negative controls with no predicted synergistic or individual dependencies on the two 301 TKs (H2170, H460, and H520). To measure sensitivity to these agents, we used two different and 302 complementary assays, including: (a) colony formation assay to assess long term sensitivity ( Fig.  303 4A and Methods) and (b) 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) 304 assay for short term sensitivity analysis ( Fig. 5A and Methods) . Across all 11 cell lines tested in colony formation assay, 8 showed significant sensitivity to either 316 individual inhibitors (H226 E,C , H2122 E , H1666 E,C , Cal-12T E , Calu-3 E,C , H1650 E ) or synergistic 317 sensitivity to the combination (HCC78 E+C and H2023 E+C ) (Fig 4B-C and Fig S3) . Surprisingly, all 318 of these cell lines were EGFR WT , ALK WT , and c-MET WT , except for H1650, which was EGFR Mut . 319
Thus, based on standard of care criteria, 7 out of 8 cell lines would not have been considered as 320 sensitive to either EGFR or ALK/c-MET inhibitors. Several cell lines presented striking sensitivity 321 to either one (H2122 E , Cal-12T E , H1650 E ) or both inhibitors (H226 E,C , H1666 E,C , Calu-3 E,C ) in 322 isolation, thus making the assessment of synergistic drug sensitivity difficult. In addition, three 323 EGFR WT cell lines harboring BRAF (Cal-12T and H1666) or KRAS (H2122) mutations were also 324 highly sensitive to Erlotinib as a single agent, as predicted by pVIPER, despite the fact that KRAS 325 pathway mutations are mutually exclusive with EGFR mutations and predictive of Erlotinib 326 resistance (Fig. 4C) . Finally, none of these cell lines was predicted to be sensitive to ALK 327 inhibitors, suggesting that Crizotinib sensitivity is mediated by c-MET specific dependencies. Of 328 the negative controls, only one (H2170) showed high sensitivity to Erlotinib. Taken together, 8/11 329 cell lines (73%) predicted as sensitive to the inhibitors were validated long term colony formation 330 assays, while only 1/3 negative controls showed sensitivity to these agents (33%). 331
332
To evaluate the short-term interaction between EGFR and c-MET, we performed MTT assay 333 across 11 cell lines (HCC78, H2023, H1650, Calu-3, H2172, H2122, H1568, A549, H1666, H520 334 and H2170) including 2 negative control cell lines (H520 and H2170). Similar to colony formation 335 assay, we found synergistic sensitivity to EGFR and c-MET inhibitors in 6/9 cell lines (67%), with 336 5 cell lines showing strong synergy (CI ≤ 0.8) ( Fig. 5B-C) and 1 borderline synergy (CI = 0.82), 337
showing the consistency between two assays. However, for two cell lines, H1666 and H2170 (a 338 negative control), results were inconsistent between long term colony formation and MTT assays. 339
For both H1666 and H2170 cell lines, colony formation and MTT assay to showed sensitivity to 340
Erlotinib alone, where colony formation assay has complete abrogation of colonies at 1 μM of 341 Erlotinib, and later had IC 50 =1.25 μM and 3.7 μM for H1666 and H2170 respectively. However, 342 in combination therapy, MTT assay showed antagonism (CI >1), despite the fact that colony 343 formation assay still showed complete abrogation which could be associated to the accumulation 344 of new mutations in these cell lines. However, this is just hypotheses and needs to be verified by 345 further experiments such as sequencing of these cell lines pre-and post-treatment. 346 347
Phosphosite specific phosphorylation predicts EGFR/c-MET inhibitor synergy. 348
In previous section, we assessed the pVIPER predictions after consolidating the result at protein 349 level. Following the results from MTT and colony formation assays, we reanalyzed the pVIPER 350 combination. For these two peptides, we found their common substrates to be hyper 367 phosphorylated in the sensitive cell lines (Fig. 6A ) compared to the specific substrates of each of 368 them, whereas cell line responding only to EGFR inhibitors showed more hyper phosphorylation 369 of EGFR only substrates (Fig. 6B) . Cell lines resistant to both EGFR and c-MET inhibitors either 370 showed no change in the phosphorylation status or hypo-phosphorylation compared to the normal 371 samples (Fig. 6C) . Hence, either the common substrates of EGFR and c-MET, or the 372 phosphorylation status of EGFR 1197 and c-MET 1003 could potentially be used as biomarkers for 373 predicting therapy with the dual inhibitors. However, this conclusion is based on a very limited 374 number of observations and lacks the statistical power. This finding needs a re-375 evaluation/validation using larger cohort of samples to establish an appropriate biomarker for 376 combination therapy. 377 378
Addictions points in patient samples 379
Similar to cell lines, when applied on patient data, pVIPER identified EGFR as one of the most 380 common addiction points (Fig. 6) . We inferred EGFR dependency in 12 patients. Of these, 5 381 harbored EGFR mutation, while the remaining 7 patients had not been tested for this mutation, 382
showing a high consistency between our predictions and the genetic predisposition for sensitivity 383 to EGFR inhibitors. In the entire cohort, there were only 3 patients with EGFR mutations that were 384 not identified as EGFR dependent by pVIPER, resulting in an overall sensitivity of 62.5% (5/8). 385
However, it is well known that >50% of patients harboring EGFR mutations do not respond to 386
Erlotinib, suggesting that these may not be false negatives but rather patients with low activation 387 of downstream EGFR pathways, despite their EGFR Mut state. Similarly, our analysis identified 388 candidate ALK dependencies in 4 patients. Of these one had an established TFG-ALK fusion, 389
whereas the others had not been tested for ALK fusion events. 390
Across all patient samples, we observed Discoidin Domain Receptor-1 (DDR1) to be the most 391 frequent addiction point, which was not predicted for any of the 46 cell lines. One reason for the 392 difference is that DDR1 is collagen dependent and there may be differences in the 3D structure 393 of the tumor and the cell lines growing on the plate. An independent study (70) in a cohort of 83 394 lung cancer specimens found that silencing of DDR1 in these samples leads to the hampering of 395 cell survival, reduced invasiveness in collagen matrices, increased apoptosis in basal condition 396 and decreased metastatic activity in model of tumor metastasis to bone, signifying it as a potential 397 novel therapeutic target. CONCLUDING SENTENCE. 398
Discussion

399
In this paper, we developed pARACNe to infer Tyrosine Kinase (TK) signaling network using 400 genome-wide phosphoproteomic data from lung cancer. The network prediction was validated 401
using SILAC experiments, with high accuracy. Interrogation of the predicted TK-substrate network 402 generated biologically meaningful hypotheses, followed by experimental validations illustrating assay data after various stimulations to cells and inferred signaling network using hidden Markov 414 models and genetic algorithms. Even though the resulting networks are context specific, they lack 415 genomic-scale coverage. There have been methods which used existing large-scale protein 416 networks and prune them using transcriptomic information to identify signaling pathways (20) (21) (22) . 417
In addition, attempts have been made to reconstruct signaling network using gene expression 418 data (23, 24). However, as signaling complexity lies mostly in upper level of cellular processes, 419 inferring the cascades from downstream gene expression fails to capture all the dynamics. Also, 420
PrePPI proposed by Zhang et al. (25) used protein structure-based methods to infer global 421 protein-protein interaction, but this approach fails to address phosphorylation context specificity. 422
Innovative uses of multiplex and microarray-based approaches, where multiple antibodies can be 423 used to probe an ensemble of phosphoproteins, are finally becoming sufficiently mature to allow 424 characterization of small pathways. Yet, these methods are still far from providing an unbiased, 425 genome-wide view of signal-transduction processes and continue to be completely dependent on 426 antibody specificity and availability. Similarly, assays developed specifically to monitor 427 phosphorylation pathways, such as Stable Isotope Labeling with Amino acids in Cell culture 428 (SILAC), provides a simple and straightforward approach to detect differential protein abundance. 429
Coupled with phosphorylation enriched assays, it can provide high quality quantification for post-430 translation phosphorylation changes in cell lines. However, these methods are 1) laborious and 431 costly; 2) can only be performed to dissect the substrates of a single enzyme at a time and 3) do 432 not differentiate between direct and indirect targets. 433
434
To be noted, as the LC-MS/MS experiments used here was generated based on Tyrosine-kinase 435 enrichment, which is only about ~2% of whole phosphoproteome. pARACNe is shown only on 436 TK-substrates network. The current methodology could be extended to whole phosphoproteomic 437 data based signaling network reconstruction where the data is available. In addition to label free 438 based LC-MS/MS proteomics data used in this work, label based approaches, such as ITRAQ or 439 TMT, could generate higher throughput whole proteomic profiles which might require future 440 redesign of ARACNe to incorporate both kinases and phosphatases in regulating their 441 downstream substrates. It is reasonable to expect that a version of ARACNe developed 442 specifically to dissect signaling networks should work at least as well as its transcriptional 443 counterpart. Since the relationship between the mRNA abundance of a gene encoding a 444 transcription factor (TF) and the activity of the corresponding protein is much looser than that 445 between the abundance of a phospho-isoform of a kinase and its enzymatic activity. Even though research has attempted to identify addiction points based on gene expression data 449 (71), predictions based on phosphoproteomic data appear superior in a way that they can directly 450 reflect contextual specific signaling activity and are able to be directly targeted by kinase 451 inhibitors. It is important to note that clinically, only patients with base-pair deletion at exon 19 452 (del746_A750) or a point mutation at exon 21 mutation (L858R) in EGFR shows sensitivity to 453 EGFR inhibitor such as Cedirinib or Erlotinib (72). showed high-levels of phospho-tyrosine expression. Immunoblotting of 46 NSCLC cell lines with 708 a phospho-tyrosine specific antibody also showed heterogeneous reactivity especially in the 709 molecular weight range characteristic of receptor tyrosine kinases. 710
Since phospho-tyrosine represents less than 1% of the cellular phosphoproteome, as determined 711 by tandem mass spectrometry (MS/MS), and is difficult to analyze by conventional methods, 712 immuno-affinity purification was performed with a phospho-tyrosine antibody to enrich for 713 phospho-tyrosine containing peptides prior to tandem mass spectrometry. All tumors were 714 identified as NSCLC based on standard pathology. Only those tumors with greater than 50% of 715 cancer cells were considered for further analysis. NSCLC cell lines were grown overnight in low 716 serum to reduce background phosphorylation from culture conditions. 717
Tandem MS profiling identified 3920 tyrosine phosphorylation sites on approximately 2600 718 different proteins. 85% of these sites appeared to be novel when compared against PhosphoSite 719 (http://www.phosphosite.org), a comprehensive resource of known phosphorylation sites. 720
